1. Home
  2. Analysis
  3. Stock
Stock

SELLAS Triples on Phase 3 Leukemia Vaccine Data Showing 41% Death Risk Reduction

SELLAS shares surged over 200% after Phase 3 REGAL trial data showed galinpepimut-S extended median survival in AML to 24.0 months, cutting death risk by 41%.

BMInsider desk · · 3 min read

Shares of SELLAS Life Sciences surged over 200% on Tuesday, November 17, 2026, after the biopharma revealed pivotal Phase 3 data showing its cancer vaccine reduced the risk of death by 41% in leukemia patients. For retail investors navigating late-stage oncology, the trial success transforms a speculative small-cap into a biopharma with a validated clinical asset poised for commercialization.

What happened

Topline results from the pivotal Phase 3 REGAL trial showed that SELLAS' lead candidate, galinpepimut-S (GPS), met its primary endpoint of overall survival (OS) in patients with acute myeloid leukemia (AML) in second or later remission. Patients treated with GPS achieved a median OS of 24.0 months compared to 14.7 months for the best available treatment arm—a statistically significant 9.3-month survival benefit (hazard ratio 0.59, p = 0.035).

The market reaction was immediate and explosive. Shares of SELLAS (NASDAQ: SLS) tripled during Tuesday's session, leaping over 200% from previous levels near $7.50 to intraday highs of $24.17 before changing hands around $22.71. Trading volume smashed historical averages as Wall Street re-priced a therapy that demonstrated no new safety signals, with adverse reactions remaining overwhelmingly mild to moderate.

Why it matters

AML in second remission carries a dismal prognosis, leaving non-transplant candidates with virtually no effective maintenance therapy. By validating its WT1-targeting mechanism in a rigorous Phase 3 setting, SELLAS has crossed the hardest hurdle in drug development, differentiating GPS from standard chemotherapies that often fail to prevent relapse.

For biotech investors familiar with extreme volatility, the clinical validation substantially derisks the clinical and regulatory outlook while opening an underserved oncology market. Financially, SELLAS entered this readout with a strengthened balance sheet, holding $134.7 million in cash as of September 30, 2026. This liquidity provides operational runway through regulatory review, although eventual commercial launch costs could still introduce financing needs and potential share dilution.

What to watch next

  • FDA Pre-BLA Meeting: Consultations with regulators regarding accelerated filing and review timelines for GPS.
  • Regulatory Submission: Formal Biologics License Application (BLA) filing targeted for the first half of 2027.
  • Commercial Strategy: Potential partnership or licensing deals for U.S. and European distribution rights.
  • Cash Burn: Quarterly R&D and commercial preparation expenditures as the company transitions toward launch.
Sources (2)
  1. SELLAS Life Sciences Announces Positive Topline Results from Pivotal Phase 3 REGAL Trial of Galinpepimut-S (GPS) in Acute Myeloid Leukemia
  2. SELLAS Life Sciences Group Reports Third Quarter 2026 Financial Results and Provides Corporate Update

This analysis is for information only and is not investment advice. Prices and figures as of publication.

AI stock analysis

Any stock analysed in minutes

Business model, balance sheet, valuation and scenarios: aktienanalyse.ai builds a thorough analysis of any stock in minutes, with a fair value and bull, base and bear cases.

Analyse a stock → Stock profiles